Teva Pharmaceuticals (NYSE:TEVA) said today that it closed the $1.1 billion cash sale of its Paragard intrauterine copper contraceptive device to Cooper Cos.‘ (NYSE:COO) CooperSurgical unit. The deal included Teva’s manufacturing facility in Buffalo, N.Y., the pharma company reported. The move is part of Teva’s efforts to restructure its business, narrowing its focus on CNS and respiratory […]
Cooper Cos. (NYSE:COO) said today it inked a deal to purchase the Paragard intrauterine device assets and business, including a Buffalo, N.Y.-based factory, from Teva Pharmaceuticals (NYSE:TEVA) for $1.1 billion in cash. The deal has been unanimously approved by both Teva and The Cooper Co.’s boards of directors, and is expected to close prior to the end of 2017, […]
Smiths Group (LON:SMIN) said today it divested its Wallace in-vitro fertilization product line to Cooper Cos. (NYSE:COO) CooperSurgical subsidiary for $174 million (UK £140 million). The divestiture is part of an ongoing program at Smiths to focus its portfolio on “market leading positions of scale in its chosen markets,” the company said. The company said that proceeds from […]
EP Global Communications (OTC:EPGL) said it’s parting ways with Cooper Cos. (NYSE:COO) subsidiary CooperVision on a co-development project for advanced contact lens technology. Irvine, Calif.-based EP Global, which last year threw the gauntlet before Google (NSDQ:GOOG) on its much-ballyhooed smart contact lens program, said the Dec. 31 settlement with CooperVision allows each company to pursue the technology on its […]
Cooper Cos. (NYSE:COO) CooperSurgical subsidiary acquired in-vitro fertilization screening company Reprogenetics last week for nearly $47 million. Livingston, N.J.-based Reprogenetics offers pre-implantation genetic screening and diagnosis for in vitro fertilization, Cooper said. The $46.5 million deal isn’t expected to affect earnings per share this year or in 2016, but should be accretive thereafter, the company said. Reprogenetics put up […]
Dockendorff has been with the company since 1989, serving in a variety of finance-related roles. He was named CFO of Covidien predecessor Tyco Healthcare in 1995, helping lead the company to $10 billion in sales in 2007.
Cooper Cos. (NYSE:COO) today announced that the U.S. Food and Drug Administration has granted a Special 510(k) clearance for CooperVision’s Avaira Toric two-week silicone hydrogel contact lenses for astigmatism.
CooperVision will re-launch Avaira Toric with shipments available for select distribution beginning in early May 2012.